Galimedix Therapeutics, Inc.

0 followers


Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to improve function in glaucoma and dry AMD – leading causes of blindness – and also in Alzheimer’s disease.

Employees

1-10

Links


Org chart

Collapse
Yaniv Barkana
Chief Medical Officer, Galimedix Therapeutics
Phyllis Bellin
Chief Financial Officer

Teams

This company has no teams yet